Metastatic Castration-Resistant Prostate Cancer
FGENFibroGen IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for FG-3180 (CD46 PET Tracer) in Metastatic Castration-Resistant Prostate Cancer. The expected timing is based on the latest available company guidance and may change.
11/10/25:- FG-3180, a CD46-targeted PET imaging agent, will be evaluated as a companion diagnostic in the ongoing Phase 2 FG-3246 monotherapy trial in metastatic castration-resistant prostate cancer, with interim trial results expected in H2 2026. 02/23/26:- Higher FG-3180 uptake trended toward greater PSA50 responses; Phase 2 monotherapy interim data still expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.